American Society of Cataract and Refractive Surgery

Opthea to Present at Eyecelerator Forum at the 2023 American Academy of Ophthalmology (AAO) Conference

Retrieved on: 
Monday, October 30, 2023
American Society of Cataract and Refractive Surgery, Refractive surgery, ASCRS, Therapy, Physician, AAO, Society, Cataract, American Academy, Surgeon, Partnership, American Academy of Ophthalmology, Patient, Retina, Pharmaceutical industry

Dr. Baldwin will present on Thursday, November 2nd at 1:36pm PST as part of Eyecelerator’s “Retina Showcase” highlighting companies advancing next generation therapeutics for retina diseases.

Key Points: 
  • Dr. Baldwin will present on Thursday, November 2nd at 1:36pm PST as part of Eyecelerator’s “Retina Showcase” highlighting companies advancing next generation therapeutics for retina diseases.
  • Eyecelerator is a partnership between the American Academy of Ophthalmology (AAO) and the American Society of Cataract and Refractive Surgery (ASCRS).
  • Its mission is to connect entrepreneurs, investors, companies, and physicians to advance ophthalmic innovation through live conferences, virtual programming, and a next-generation networking platform.
  • The Academy innovates to advance the profession and to ensure the delivery of the highest-quality eye care.

Hexiris Pharma Welcomes World-Renowned Ophthalmologist Dr. Ike Ahmed to its Scientific Committee

Retrieved on: 
Monday, October 30, 2023
Knowledge, American Academy of Ophthalmology, FDA, Research, AGS, American Glaucoma Society, Vision, Slit lamp, ASCRS, Refractive surgery, ISGS, Glaucoma, MIGS, Pressure, MD, University of Utah, AAO, Glaucoma surgery, Alan, University, COS, Cataract, Trillium Health Partners, University of Toronto, Eye, Visual Science, CGS, American Society of Cataract and Refractive Surgery, International Society, ARVO, Scientific Committee on Emerging and Newly Identified Health Risks, Patient, Diagnosis, Medical device, Ophthalmology

DIEPPE, New Brunswick, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Hexiris Pharma Inc. (“Hexiris Pharma” or the “Company”), a pharmaceutical firm dedicated to advancing and simplifying Minimally Invasive Glaucoma Surgery (MIGS), is pleased to announce that world-renowned ophthalmologist Dr. Ike Ahmed will join Hexiris Pharma’s Scientific Committee.

Key Points: 
  • DIEPPE, New Brunswick, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Hexiris Pharma Inc. (“Hexiris Pharma” or the “Company”), a pharmaceutical firm dedicated to advancing and simplifying Minimally Invasive Glaucoma Surgery (MIGS), is pleased to announce that world-renowned ophthalmologist Dr. Ike Ahmed will join Hexiris Pharma’s Scientific Committee.
  • “We are truly honoured that Dr. Ahmed has agreed to join Hexiris Pharma’s Scientific Committee,” said Dr. Nir Shoham-Hazon, Co-Founder and Co-CEO of Hexiris Pharma.
  • I’m pleased to be joining the Scientific Committee at Hexiris Pharma and join in the important work of improving the lives of patients and bringing new solutions and opportunities to ophthalmologists,” said Dr. Ahmed.
  • He has given over 750 scientific presentations thus far in his career, including 31 visiting professor’s lectures around the world.

Jimmy O. Yang Partners with STAAR Surgical to Shine a Light on Their Vision Correction Lens, EVO ICL

Retrieved on: 
Tuesday, October 10, 2023
Partnership, ICL, Lens, American Society of Cataract and Refractive Surgery, Ophthalmology, Eye, Human, Refractive surgery, Society, Patient satisfaction, Interior Chinatown, Crazy Rich Asians, Near-sightedness, EVO, FDA, Iris, Astigmatism, Cataract, Literature, CCRS, Learning, Intraocular lens, ASCRS, Silicon, Patient, Medical device, Telescopic sight, LASIK, Diadenosine hexaphosphate hydrolase (AMP-forming)

This partnership brings together EVO Implantable Collamer® Lenses (EVO ICL) for nearsightedness and astigmatism and the voice of Jimmy O. Yang.

Key Points: 
  • This partnership brings together EVO Implantable Collamer® Lenses (EVO ICL) for nearsightedness and astigmatism and the voice of Jimmy O. Yang.
  • The EVO ICL vision correction procedure has been a life-changing experience for him.
  • "Like with Jimmy O. Yang, I am seeing an increasing number of patients who qualify for both EVO ICL and laser vision correction opting for the lens-based surgery.
  • EVO ICL represents a significant advancement in vision correction technology as it works in harmony with the natural eye.

HelpMeSee announces Dr. Bonnie An Henderson as president and CEO

Retrieved on: 
Tuesday, October 10, 2023
Ueltschi, Dartmouth College, Refractive surgery, Society, Defense, Medicine, Tufts University School of Dental Medicine, Visual impairment, Tufts University School of Medicine, Department of Defence, Paratriathlon, Journal, American Society of Cataract and Refractive Surgery, Cataract, Harvard Medical School, Publication, Massachusetts Eye and Ear, Geisel School of Medicine, Journal of Refractive Surgery, Woman, Management, Ophthalmology

JERSEY CITY, N.J., Oct. 10, 2023 /PRNewswire/ -- HelpMeSee, the global mission to end cataract blindness by vastly expanding access to high quality, affordable treatment, has elected Dr. Bonnie An Henderson as its President and CEO effective immediately.

Key Points: 
  • JERSEY CITY, N.J., Oct. 10, 2023 /PRNewswire/ -- HelpMeSee, the global mission to end cataract blindness by vastly expanding access to high quality, affordable treatment, has elected Dr. Bonnie An Henderson as its President and CEO effective immediately.
  • Dr. Henderson is an internationally recognized expert in cataract and refractive surgery, with a distinguished career that includes past presidency of the American Society of Cataract and Refractive Surgery.
  • Dr. Bonnie An Henderson said, "My entire professional career as a cataract surgeon and educator has led me to HelpMeSee.
  • Jim Ueltschi, founder, and chairman of the board of directors at HelpMeSee stated that "We are delighted and flattered that Bonnie is our CEO and President.

The Inner Circle Acknowledges, Joseph P. Calderone as a Top Pinnacle Healthcare Professional for his contributions to the field of Ophthalmology

Retrieved on: 
Friday, September 1, 2023
Seton Hall University School of Law, Medicine, College, Refractive surgery, American Board of Ophthalmology, ABO, Surgery, Central Jersey, Fellow of the American College of Surgeons, Holy Cross, Regius Professor, Graduate medical education, American Academy, American Academy of Ophthalmology, Multimedia, Cataract, New York Medical College, New Jersey Academy of Science, Albany Medical Center, Inner circle, American Society of Cataract and Refractive Surgery, American Board of Commissioners for Foreign Missions, Patient, Physician, Betancourt v. Trinitas Hospital, New Jersey Medical School, American College, Overlook Medical Center, Catali (footballer), Family, Society, Nursing, Ophthalmology, Chemistry

CRANFORD, N.J., Sept. 1, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Joseph P. Calderone is acknowledged as a Top Pinnacle Healthcare Professional for his contributions to the field of Ophthalmology.

Key Points: 
  • CRANFORD, N.J., Sept. 1, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Joseph P. Calderone is acknowledged as a Top Pinnacle Healthcare Professional for his contributions to the field of Ophthalmology.
  • Dr. Calderone began his scholarship at the College of the Holy Cross where he graduated with a Bachelor of Arts degree in Chemistry.
  • The doctor currently works as the Medical and Surgical Director of Better Vision New Jersey (formerly called Cranford Ophthalmology) where he has served since 1987.
  • Dr. Calderone would like to dedicate this honor in loving memory of his father, Joseph P. Calderone, and thanks his wife Heidi, and daughters.

OKYO Pharma Limited Reports Annual Results for the Twelve Months Ended March 31, 2023

Retrieved on: 
Tuesday, August 15, 2023
DED, Refractive surgery, Investigational New Drug, Clinical trial, Quality of life, Research, ASCRS, American Society of Cataract and Refractive Surgery, Telecanthus, Placebo, Tufts Medical Center, Patient, NCP, R, Cataract, FDA, IND, Society, Safety, Pharmaceutical industry, Cryptocurrency

On May 2, 2023, we announced the initiation of our first clinical trial of OK-101 to treat DED.

Key Points: 
  • On May 2, 2023, we announced the initiation of our first clinical trial of OK-101 to treat DED.
  • For the twelve months ended 31 March 2023 OKYO reported a loss of $13.7 million compared to $6.3 million in the twelve months ended 31 March 2022.
  • Research and development (R&D) expenses increased to $6.3 million for the twelve months ended 31 March 2023 compared to $1.6 million in the twelve months ended 31 March 2022.
  • OKYO ended the period with $4.0 million cash as of 31 March 2023 as compared to $2.7 million on 31 March 2022.

HelpMeSee announces Dr. Bonnie Henderson as interim president and CEO

Retrieved on: 
Tuesday, August 15, 2023
Abstract, Tufts University School of Medicine, Refractive surgery, Teaching, Henderson, Cataract, Journal of Refractive Surgery, Visual impairment, Woman, Medicine, Paratriathlon, Dartmouth College, Massachusetts Eye and Ear, Tufts University School of Dental Medicine, American Society of Cataract and Refractive Surgery, Harvard Medical School, Journal, Geisel School of Medicine, Society, Management, Veterinary medicine, Ophthalmology

JERSEY CITY, N.J., Aug. 15, 2023 /PRNewswire/ -- Dr. Bonnie Henderson has been named interim president and CEO of HelpMeSee, a global nonprofit that provides cataract treatment training using its innovative simulation-based training system to vastly increase access to treatment and eradicate cataract blindness.

Key Points: 
  • JERSEY CITY, N.J., Aug. 15, 2023 /PRNewswire/ -- Dr. Bonnie Henderson has been named interim president and CEO of HelpMeSee, a global nonprofit that provides cataract treatment training using its innovative simulation-based training system to vastly increase access to treatment and eradicate cataract blindness.
  • Dr. Henderson, an internationally recognized expert in cataract and refractive surgery, is a past president of the American Society of Cataract and Refractive Surgery and a clinical professor at Tufts University School of Medicine.
  • Her textbook "Essentials of Cataract Surgery" is among the most used textbooks for teaching cataract surgery in the United States.
  • In addition, Dr. Henderson created EnVision Summit, an international ophthalmology meeting to support and empower women leaders in medicine.

Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update

Retrieved on: 
Friday, August 11, 2023
Purchasing, Interim, ARVO, American Diabetes Association, Refractive surgery, DME, DLD, Presbyopia, DRSS, Research, ASCRS, American Society of Cataract and Refractive Surgery, OCUP, Sales management, Patient, Agency, Risk, Annual general meeting, PDUFA, Power purchase agreement, Diabetic retinopathy, Association for Research in Vision and Ophthalmology, Security (finance), Cataract, FDA, ADA, LPC, Society, Safety, Pharmaceutical industry, Medical device, Cryptocurrency, RM, Ophthalmology

FARMINGTON HILLS, Mich., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced financial results for the second quarter ended June 30, 2023, and provided a corporate update.

Key Points: 
  • FDA approval in RM would trigger a $10 million milestone payment to Ocuphire
    In July 2023, Ocuphire confirmed an End-of-Phase 2 meeting with the FDA, scheduled for the fourth quarter of 2023.
  • On August 10, 2023, Ocuphire entered into a common share purchase agreement (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (LPC), an institutional investor.
  • Second Quarter ended June 30, 2023 Financial Highlights
    As of June 30, 2023, Ocuphire had cash and cash equivalents of approximately $40.0 million.
  • For further details on Ocuphire’s financial results, refer to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 to be filed with the Securities and Exchange Commission.

STAAR Surgical Teams Up With Tennessee Titans Quarterback Will Levis On Life Changing Vision Correction Procedure, EVO ICL

Retrieved on: 
Wednesday, August 9, 2023
Men, Sports, Entertainment, General Sports, Optical, Licensing (Sports), Consumer, Medical Devices, Football, Celebrity, Surgery, Women, Health, Contact, Learning, NFL, Intraocular lens, Partnership, Refractive surgery, Education, Nave, Patient satisfaction, Tennessee Titans, Eye, Lens, Ophthalmology, Glasses, Multimedia, ASCRS, Quality, Athlete, Will Levis, American Society of Cataract and Refractive Surgery, Literature, National Football League, Astigmatism, Near-sightedness, Cataract, FDA, Society, Iris, Levis, EVO, Telescopic sight, Medical device, LASIK, Life, Patient

EVO ICL is proud to provide athletes like Levis with sharp1,2 vision day or night1,3, on and off the field.

Key Points: 
  • EVO ICL is proud to provide athletes like Levis with sharp1,2 vision day or night1,3, on and off the field.
  • View the full release here: https://www.businesswire.com/news/home/20230809191942/en/
    Will Levis, Titans QB, upgraded his vision with EVO ICL.
  • (Photo: Business Wire)
    The FDA-approved EVO ICL lenses are successful in correcting myopia, which affects distance vision, and myopia with astigmatism, which causes blurred vision at all distances.
  • Once he learned about EVO ICL and all of its benefits, EVO became an easy choice for him,” said Tom Frinzi, CEO of STAAR Surgical.

American Academy of Ophthalmology: Georgia's Medicare Advantage Beneficiaries Get Relief from Abusive Prior Authorization Policy

Retrieved on: 
Thursday, August 3, 2023
Pressure, Medicare Advantage, United States House Committee on Ways and Means, Refractive surgery, Coalition, Cataract, Policy, Quality of life, American Academy, ASCRS, Falls, Medicine, Dementia, American Society of Cataract and Refractive Surgery, Organization, Congress, YAG, Capsulotomy, Patient, Physician, Risk, SAN, American Academy of Ophthalmology, Regulation, House Committee, Society, Safety, Legislation, Veterinary medicine, Health insurance, Pharmaceutical industry, Humana, Medicare, Ophthalmology, MD

SAN FRANCISCO, Aug. 3, 2023 /PRNewswire/ -- The American Academy of Ophthalmology, the American Society of Cataract and Refractive Surgery (ASCRS), and the Georgia Society of Ophthalmology applaud Humana for rolling back its prior authorization requirement for cataract surgery for Medicare Advantage beneficiaries in Georgia. Last year, Humana began requiring pre-approval through iCare Health Solutions for all cataract and posterior capsulotomy (or YAG laser capsulotomy) surgeries. This irrational policy caused unnecessary treatment delays and denials for people in Georgia who needed surgery to restore their sight. Humana's decision is effective August 1.

Key Points: 
  • One month after Aetna's partial reversal, Humana instituted its own prior authorization policy for cataract surgery patients living in Georgia.
  • "We will continue to pressure Aetna to retract its policy for people enrolled in Medicare Advantage in Florida and Georgia."
  • The Academy is urging Congress to seize on this momentum and get commonsense prior authorization reforms signed into law this year.
  • "Medicare Advantage plans have greatly expanded the use of prior authorization over the years, putting profits over patients.